Balchem Delivers Record-Breaking Quarter: Unprecedented Growth Across All Segments
The biotechnology company Balchem Corporation has announced its second quarter 2026 earnings, showcasing a remarkable performance that sets new records in consolidated sales, adjusted EBITDA, and adjusted net earnings. Chairman, President, and CEO Ted Harris highlighted the company's strong growth across all three segments during the call.
Human Nutrition & Health led the charge with another very strong quarter, driven by solid demand for nutrients portfolio and food ingredients and solutions businesses. The heightened interest in supplementation and healthier nutrient-dense products continues to create opportunities for customers and subsequently, Balchem's science-based ingredients, formulation expertise, and application capabilities.
In Animal Nutrition & Health, the company generated healthy growth due to expanding adoption of precision-release rumen-protected nutrient technologies within the dairy industry, as well as higher year-over-year volumes and margins in European monogastric business. The momentum across Balchem's Animal Nutrition & Health portfolio remains encouraging, providing value to producers seeking greater efficiency, productivity, and sustainability.
Specialty products also drove healthy top and bottom-line growth on solid volume and pricing growth, particularly within the performance gases business. Demand trends across Balchem's businesses remain healthy, with each segment performing well despite higher input costs related to the conflict in the Middle East. The company managed to mitigate these costs through a combination of actions and growth-driven operating leverage.
On the capital allocation front, Balchem took several key steps during the quarter to enhance financial flexibility and return capital to shareholders. Firstly, the company recently completed the refinancing of its revolving credit facility, increasing borrowing capacity from $550 million to $650 million and extending the maturity into 2031. This transaction further strengthens Balchem's financial position, providing additional flexibility to support growth strategy, including continued investment in innovation, capacity expansion, and strategic acquisition opportunities.
Secondly, Balchem repurchased approximately $29 million of common stock during the second quarter and $114 million over the trailing 12 months. This reflects a continued commitment to disciplined capital allocation and shareholder value creation.
The company's strong performance in Q2 2026 serves as a testament to its solid execution on strategic growth initiatives, driven by healthy market penetration of unique portfolio of specialty nutrients and delivery systems, as well as favorable better-for-you trends within the food and nutrition markets. As Ted Harris noted, Balchem remains confident in its ability to drive continued growth and margin performance going forward.
